substance;substance_identifier;membrane;method;charge;temperature;note;x_min;x_min_acc;g_pen;g_pen_acc;g_wat;g_wat_acc;log_k;log_k_acc;log_perm;log_perm_acc;primary_publication;secondary_publication
(2R)-N-methyl-1-phenyl-N-prop-2-ynylpropan-2-amine;MM00565;Caco2/MDCK;CPapp;0;37;;;;;;;;;;-4.36653;;;"Bittermann K, Goss KU.: Predicting apparent passive permeability of Caco-2 and MDCK cell-monolayers: A mechanistic model. PLoS One, Volume 12 (12), e0190319, 2017"
(2R)-N-methyl-1-phenyl-N-prop-2-ynylpropan-2-amine;MM00565;MDCK;EMDCK;;37;;;;;;;;;;-4.15304;;;"Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW.: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther, Volume 303 (3), 1029-1037, 2002"
(2R)-N-methyl-1-phenyl-N-prop-2-ynylpropan-2-amine;MM00565;1-octanol;XLOGP3;;;;;;;;;;2.8;;;;;"Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, Li Q, Shoemaker BA, Thiessen PA, Yu B, Zaslavsky L, Zhang J, Bolton EE.: PubChem 2023 update. Nucleic Acids Res, Volume 51 (d1), D1373-D1380, 2023"
(2R)-N-methyl-1-phenyl-N-prop-2-ynylpropan-2-amine;MM00565;DOPC;CCM18;0;25;;;;;;;;;;-0.65;;;"in-house calculations"